For one thing, the patients in the placebo arm of the study appeared to be sicker, older, and more refractory to prior chemotherapy than those in the elesclomol arm.
With the small absolute event numbers and lack of a comparator arm in the study (only 7% of patient-days were on placebo), we view the move in the shares as an overreaction.